🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2026-525844-14-00
Authorised Phase I

Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants with End-Stage Kidney Disease on Hemodialysis

2026-525844-14-00 · tracked via the Priya Life Science EU tracker
Sponsor
Regeneron Pharmaceuticals Inc.
Sponsor type
Pharmaceutical company
Therapeutic area
Hemic and Lymphatic Diseases
Decision date
03/07/2026
Enrollment target
36
Sites
Belgium

Condition studied

End-Stage Kidney Disease (ESKD)

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-525844-14-00 on CTIS ↗ ← All trials in the EU